BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Battah B, Chemi G, Butini S, Campiani G, Brogi S, Delogu G, Gemma S. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. Molecules 2019;24:E4373. [PMID: 31795400 DOI: 10.3390/molecules24234373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Come JAADSS, Zhuang Y, Li T, Brogi S, Gemma S, Liu T, da Silva ER. In Vitro and In Silico Analyses of New Cinnamid and Rosmarinic Acid-Derived Compounds Biosynthesized in Escherichia coli as Leishmania amazonensis Arginase Inhibitors. Pathogens 2022;11:1020. [DOI: 10.3390/pathogens11091020] [Reference Citation Analysis]
2 Kim LH, Kang SM, Whang J, Kwon KW, Shin SJ. Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection. Antimicrob Agents Chemother 2022;:e0076222. [PMID: 36040172 DOI: 10.1128/aac.00762-22] [Reference Citation Analysis]
3 Perveen S, Kumari D, Singh K, Sharma R. Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. Eur J Med Chem 2022;229:114066. [PMID: 34973508 DOI: 10.1016/j.ejmech.2021.114066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 She P, Li S, Zhou L, Liu Y, Xu L, Hussain Z, Li Y, Li Z, Liu S, Wu Y. Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus. Front Microbiol 2022;12:790686. [DOI: 10.3389/fmicb.2021.790686] [Reference Citation Analysis]
5 Brogi S, Calderone V. Artificial Intelligence in Translational Medicine. IJTM 2021;1:223-85. [DOI: 10.3390/ijtm1030016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ezquerra-Aznárez JM, Almeida da Silva PE, Aínsa JA. Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs. Microorganisms 2021;9:2335. [PMID: 34835459 DOI: 10.3390/microorganisms9112335] [Reference Citation Analysis]
7 Maitra A, Evangelopoulos D, Chrzastek A, Martin LT, Hanrath A, Chapman E, Hailes HC, Lipman M, McHugh TD, Waddell SJ, Bhakta S. Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. J Antimicrob Chemother 2020;75:3194-201. [PMID: 32790867 DOI: 10.1093/jac/dkaa307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
8 Bittencourt TL, da Silva Prata RB, de Andrade Silva BJ, de Mattos Barbosa MG, Dalcolmo MP, Pinheiro RO. Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria. Front Immunol 2021;12:674241. [PMID: 34113346 DOI: 10.3389/fimmu.2021.674241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 De Maio F, Cingolani A, Bianco DM, Salustri A, Palucci I, Sanguinetti M, Delogu G, Sali M. First description of the katG gene deletion in a Mycobacterium tuberculosis clinical isolate and its impact on the mycobacterial fitness. Int J Med Microbiol 2021;311:151506. [PMID: 33906074 DOI: 10.1016/j.ijmm.2021.151506] [Reference Citation Analysis]
10 Rajput A, Kumar A, Megha K, Thakur A, Kumar M. DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses. Brief Bioinform 2021;22:1076-84. [PMID: 33480398 DOI: 10.1093/bib/bbaa421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
11 De Maio F, Salustri A, Battah B, Palucci I, Marchionni F, Bellesi S, Palmieri V, Papi M, Kramarska E, Sanguinetti M, Sali M, Berisio R, Delogu G. PE_PGRS3 ensures provision of the vital phospholipids cardiolipin and phosphatidylinositols by promoting the interaction between M. tuberculosis and host cells. Virulence 2021;12:868-84. [PMID: 33757409 DOI: 10.1080/21505594.2021.1897247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Muñoz-Torrero D. The Cream of the Crop of the Medicinal Chemistry Section of Molecules-2019. Molecules 2021;26:1053. [PMID: 33671435 DOI: 10.3390/molecules26041053] [Reference Citation Analysis]
13 Mahfuz AMUB, Stambuk Opazo F, Aguilar LF, Iqbal MN. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics. J Biomol Struct Dyn 2020;:1-17. [PMID: 33251968 DOI: 10.1080/07391102.2020.1852966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dalberto PF, de Souza EV, Abbadi BL, Neves CE, Rambo RS, Ramos AS, Macchi FS, Machado P, Bizarro CV, Basso LA. Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. Front Chem 2020;8:586294. [PMID: 33330374 DOI: 10.3389/fchem.2020.586294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Juárez-López D, Schcolnik-Cabrera A. Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments. Arch Med Res 2021;52:243-51. [PMID: 33190955 DOI: 10.1016/j.arcmed.2020.10.021] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Morofuji Y, Nakagawa S. Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning. Curr Pharm Des 2020;26:1466-85. [PMID: 32091330 DOI: 10.2174/1381612826666200224112534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mourenza Á, Gil JA, Mateos LM, Letek M. Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing. Antibiotics (Basel) 2020;9:E550. [PMID: 32872158 DOI: 10.3390/antibiotics9090550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 De Maio F, Palmieri V, Santarelli G, Perini G, Salustri A, Palucci I, Sali M, Gervasoni J, Primiano A, Ciasca G, Sanguinetti M, De Spirito M, Delogu G, Papi M. Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment. Nanomaterials (Basel) 2020;10:E1431. [PMID: 32707988 DOI: 10.3390/nano10081431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
19 Gemma S. Structure-Based Design of Biologically Active Compounds. Molecules 2020;25:E3115. [PMID: 32650470 DOI: 10.3390/molecules25143115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Nirmal CR, Ebenezer RS, Kannan P, Balasubramanian M, Thirunavukkarasu I, Mondal R, Dusthackeer A. Anti-tuberculosis activity of bio-active compounds from Lantana camara L., Euphorbia hirta L., Mukia maderaspatana (L.) M. Roem, and Abutilon indicum (L.). European Journal of Integrative Medicine 2020;35:101105. [DOI: 10.1016/j.eujim.2020.101105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhang Y, Zheng Q, Zhou Y, Liu S. Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy. Front Pharmacol 2020;11:248. [PMID: 32218733 DOI: 10.3389/fphar.2020.00248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]